ctDNA-guided surveillance and treatment monitoring in breast cancer

In this week’s VJOncology podcast, we are delighted to bring you the latest advances in circulating tumor DNA (ctDNA)-informed monitoring and follow-up strategies in breast cancer. Join leading experts Wolfgang Janni, MD, University of Ulm, Ulm, Germany, Arielle Medford, MD, Massachusetts General Cancer Center, Boston, MA, Seth Wander, MD, PhD, Massachusetts General Hospital, Boston, MA, and Rinath Jeselsohn, MD, Dana-Farber Cancer Institute, Boston, MA, as they explore cutting-edge data from key studies including SURVIVE, LEADER, a Phase I/II trial of vepdegestrant, and PACE. Together, they discuss the evolving role of circulating tumor DNA in detecting molecular relapse, guiding early intervention strategies, monitoring treatment response, and predicting resistance across early and advanced ER+/HER2-negative and HR+/HER2-negative breast cancer settings.